430 related articles for article (PubMed ID: 33564763)
1. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.
Gorman MJ; Patel N; Guebre-Xabier M; Zhu A; Atyeo C; Pullen KM; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yaun D; Bowman K; Zhou B; Maciejewski S; McGrath ME; Logue J; Frieman MB; Montefiori D; Mann C; Schendel S; Amanat F; Krammer F; Saphire EO; Lauffenburger D; Greene AM; Portnoff AD; Massare MJ; Ellingsworth L; Glenn G; Smith G; Alter G
bioRxiv; 2021 Feb; ():. PubMed ID: 33564763
[TBL] [Abstract][Full Text] [Related]
2. Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.
Alter G; Gorman M; Patel N; Guebre-Xabier M; Zhu A; Atyeo C; Pullen K; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yuan D; Bowman K; Zhou B; Maciejewski S; McGrath M; Logue J; Frieman M; Montefiori D; Schendel S; Saphire EO; Lauffenburger D; Greene A; Portnoff A; Massare M; Ellingsworth L; Glenn G; Smith G; Mann C; Amanat F; Krammer F
Res Sq; 2021 Feb; ():. PubMed ID: 33619473
[TBL] [Abstract][Full Text] [Related]
3. Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination.
Gorman MJ; Patel N; Guebre-Xabier M; Zhu AL; Atyeo C; Pullen KM; Loos C; Goez-Gazi Y; Carrion R; Tian JH; Yuan D; Bowman KA; Zhou B; Maciejewski S; McGrath ME; Logue J; Frieman MB; Montefiori D; Mann C; Schendel S; Amanat F; Krammer F; Saphire EO; Lauffenburger DA; Greene AM; Portnoff AD; Massare MJ; Ellingsworth L; Glenn G; Smith G; Alter G
Cell Rep Med; 2021 Sep; 2(9):100405. PubMed ID: 34485950
[TBL] [Abstract][Full Text] [Related]
4. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine.
Underwood E; Dunkle LM; Madhi SA; Gay CL; Heath PT; Kotloff KL; Smith K; Chau G; Galbiati S; McGarry A; Woo W; Cho I; Alves K; Áñez G; Bennett C; Shinde V; Fries L; Mallory RM; Glenn GM; Toback S
Expert Rev Vaccines; 2023; 22(1):501-517. PubMed ID: 37246757
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
Tian JH; Patel N; Haupt R; Zhou H; Weston S; Hammond H; Logue J; Portnoff AD; Norton J; Guebre-Xabier M; Zhou B; Jacobson K; Maciejewski S; Khatoon R; Wisniewska M; Moffitt W; Kluepfel-Stahl S; Ekechukwu B; Papin J; Boddapati S; Jason Wong C; Piedra PA; Frieman MB; Massare MJ; Fries L; Bengtsson KL; Stertman L; Ellingsworth L; Glenn G; Smith G
Nat Commun; 2021 Jan; 12(1):372. PubMed ID: 33446655
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
[TBL] [Abstract][Full Text] [Related]
8. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
Guebre-Xabier M; Patel N; Tian JH; Zhou B; Maciejewski S; Lam K; Portnoff AD; Massare MJ; Frieman MB; Piedra PA; Ellingsworth L; Glenn G; Smith G
Vaccine; 2020 Nov; 38(50):7892-7896. PubMed ID: 33139139
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
10. A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses.
Wilkinson B; Patel KS; Smith K; Walker R; Wang C; Greene AM; Smith G; Smith ER; Gurwith M; Chen RT;
Vaccine; 2023 Oct; 41(45):6762-6773. PubMed ID: 37739888
[TBL] [Abstract][Full Text] [Related]
11. NVX-CoV2373-induced cellular and humoral immunity towards parental SARS-CoV-2 and VOCs compared to BNT162b2 and mRNA-1273-regimens.
Hielscher F; Schmidt T; Klemis V; Wilhelm A; Marx S; Abu-Omar A; Ziegler L; Guckelmus C; Urschel R; Sester U; Widera M; Sester M
J Clin Virol; 2022 Dec; 157():105321. PubMed ID: 36279695
[TBL] [Abstract][Full Text] [Related]
12. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Formica N; Mallory R; Albert G; Robinson M; Plested JS; Cho I; Robertson A; Dubovsky F; Glenn GM;
PLoS Med; 2021 Oct; 18(10):e1003769. PubMed ID: 34597298
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Madhi SA; Moodley D; Hanley S; Archary M; Hoosain Z; Lalloo U; Louw C; Fairlie L; Fouche LF; Masilela MSL; Singh N; Grobbelaar C; Ahmed K; Benadé G; Bhikha S; Bhorat AE; Bhorat Q; Joseph N; Dheda K; Esmail A; Foulkes S; Goga A; Oommen Jose A; Kruger G; Kalonji DJ; Lalloo N; Lombaard JJ; Lombard Koen A; Kany Luabeya A; Mngqibisa R; Petrick FG; Pitsi A; Tameris M; Thombrayil A; Vollgraaff PL; Cloney-Clark S; Zhu M; Bennett C; Albert G; Faust E; Plested JS; Fries L; Robertson A; Neal S; Cho I; Glenn GM; Shinde V;
Lancet HIV; 2022 May; 9(5):e309-e322. PubMed ID: 35489376
[TBL] [Abstract][Full Text] [Related]
14. Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.
Zhu DY; Gorman MJ; Yuan D; Yu J; Mercado NB; McMahan K; Borducchi EN; Lifton M; Liu J; Nampanya F; Patel S; Peter L; Tostanoski LH; Pessaint L; Van Ry A; Finneyfrock B; Velasco J; Teow E; Brown R; Cook A; Andersen H; Lewis MG; Lauffenburger DA; Barouch DH; Alter G
PLoS Biol; 2022 May; 20(5):e3001609. PubMed ID: 35512013
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.
Bennett C; Rivers EJ; Woo W; Bloch M; Cheung K; Griffin P; Mohan R; Deshmukh S; Arya M; Cumming O; Neville AM; Pardey TM; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Buchanan A; Marcheschi A; Swan J; Smith G; Cho I; Glenn GM; Walker R; Mallory RM
J Infect Dis; 2023 Nov; ():. PubMed ID: 37970668
[TBL] [Abstract][Full Text] [Related]
16. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines.
Sheng WH; Lin PH; Cheng YC; Wu YY; Hsieh MJ; Yang HC; Chang SY; Chang SC
J Formos Med Assoc; 2024 Mar; 123(3):340-346. PubMed ID: 37996322
[TBL] [Abstract][Full Text] [Related]
18. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates.
Francica JR; Flynn BJ; Foulds KE; Noe AT; Werner AP; Moore IN; Gagne M; Johnston TS; Tucker C; Davis RL; Flach B; O'Connell S; Andrew SF; Lamb E; Flebbe DR; Nurmukhambetova ST; Donaldson MM; Todd JM; Zhu AL; Atyeo C; Fischinger S; Gorman MJ; Shin S; Edara VV; Floyd K; Lai L; Boyoglu-Barnum S; Van De Wetering R; Tylor A; McCarthy E; Lecouturier V; Ruiz S; Berry C; Tibbitts T; Andersen H; Cook A; Dodson A; Pessaint L; Van Ry A; Koutsoukos M; Gutzeit C; Teng IT; Zhou T; Li D; Haynes BF; Kwong PD; McDermott A; Lewis MG; Fu TM; Chicz R; van der Most R; Corbett KS; Suthar MS; Alter G; Roederer M; Sullivan NJ; Douek DC; Graham BS; Casimiro D; Seder RA
Sci Transl Med; 2021 Aug; 13(607):. PubMed ID: 34315825
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults.
Raiser F; Davis M; Adelglass J; Cai MR; Chau G; Cloney-Clark S; Eickhoff M; Kalkeri R; McKnight I; Plested J; Zhu M; Dunkle LM;
Vaccine; 2023 Sep; 41(41):5965-5973. PubMed ID: 37652823
[TBL] [Abstract][Full Text] [Related]
20. Protein vaccine NVX-CoV2373 elicits functional T cell immunity.
Zhou P
J Clin Invest; 2022 Oct; 132(19):. PubMed ID: 36189797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
